October 2020 Vol 11, No 10
Did you attend our virtual Midyear Conference in May? It was an incredible event! At first, the thought of switching our usual in-person conference to a virtual one was a bit disappointing to me. But there were several elements of that experience that made the virtual conference one of my all-time favorites.
Jeffrey G. Bell, Michelle Secic, Lynn E. Shaffer, Emily R. Aldrich, Valerie A. Schott, Carolyn Taylor, Kelly Reynolds, Tamara McMath, John O. Elliott
The authors report results from their prospective study of the effect of a patient navigation program on distress and health-related quality of life.
Osimertinib in the adjuvant treatment setting significantly improves disease-free survival (DFS) in patients with localized non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation.
A strong screening program can make a big difference. Here are tips for your program from the Maine Lung Cancer Coalition.
For some patients, the use of CAR-T cell therapy has resulted in robust and durable (>95%) responses lasting longer than 5 years. Here’s what you need to know about CAR T-cell therapy.
What you need to know about lessening the burden of a metastatic diagnosis.
Fertility preservation is a time-sensitive and logistic-heavy process. Are you having the right conversations with your patients?
With a follow-up of >5 years, women with relapsed platinum-sensitive ovarian cancer and a BRCA mutation who participated in the multicenter phase 3 SOLO2 trial lived >1 year longer if randomized to maintenance olaparib compared with placebo, according to data released at the ASCO20 Virtual Scientific Program.
Learn how to assess and recognize distress in your patients – and what you can do about it.
There’s a new standard of care in the first-line setting for a subset of patients with advanced colorectal cancer.
Results 1 - 11 of 11